Kornimate/medical-research-clean huggingface dataset:
effect of vitamin e for prevention of retinopathy of prematurity: a randomized clinical trial.

Conditions: Retinopathy of Prematurity

Summary: the retinopathy of prematurity (rop) is a public health problem, the main causes of rop are prematurity, use of oxygen, malnutrition and oxidative stress. vitamin e was used beforehand however its use was stopped because of its association with sepsis and enterocolitis caused by the excipient of vitamin e. the purpose of this study is to use vitamin e to prevent rop, without the previously used excipients.

antioxidant defence mechanisms include cellular and extracellular enzymes. vitamin e is the main fat-soluble vitamin responsible for the protection of cell membranes against peroxidation, thus, it protects polyunsaturated fatty acids from peroxidation which is a step in the pathogenesis of rop. previous research on the roles of vitamin e, in the prevention of bpd and rop was halted because of complications involving sepsis and necrotising enterocolitis. these complications were caused by the compositions of vitamin e oral presentations, which contain polyethylene glycol, propylene glycol, ethanol and, polysorbate 80. these substances, which are used as excipients, may generate adverse effects in premature newborns. these preparations were not used in this project to avoid the development of necrotising enterocolitis, and because these formulations are not commercially available in mexico. the infants were randomly assigned to one of two groups using a computerized random number generator sequence; this process was handled by the hospital pharmacy staff. the treated group, received vitamin e 12.5 iu orally every 12 hours, from 72 h after birth until 28 days of age, the first blood sample collected from the newborns before the intervention was considered the baseline, and subsequent samples were obtained at 15 and 28 days of age. control group: received orally sterile water (placebo)

Eligibility criteria:
inclusion criteria: * newborn weight \< 1500 g * diagnosed respiratory distress syndrome (rds) * patients who required mechanical ventilation or cpap exclusion criteria: * congenital malformations * rh incompatibility * non-immune or immune hydrops fetalis * intraventricular haemorrhage iii/iv grade

Keywords: oxidative damage vitamin e total antioxidant capacity retinopathy of prematurity
factors influencing response to one bont-a injection cycle in subjects suffering from idiopathic cervical dystonia

Conditions: Idiopathic Cervical Dystonia

Summary: a post marketing, international, multicenter, observational, prospective, longitudinal study. the purpose of the study is to describe cervical dystonia sub-types with their injection protocols and response to bont-a.


Eligibility criteria:
inclusion criteria: * idiopathic cervical dystonia * twstrs severity score ≥ 15 * at least a 12-week interval between the last injection (bont-a or bontb) and inclusion * written informed consent prior to collect the data exclusion criteria: * contraindications to any bont-a preparations * secondary cervical dystonia * subject already been included in the study
response of aerobic capacity to low level laser therapy in burned patients

Conditions: Burns

Summary: severe burns can decrease pulmonary function and impair aerobic capacity persisting for long times post injury. low level laser therapy is a new modality used to improve aerobic capacity, enhance exercise performance, increase time until fatigue when used prior to aerobic exercises. this study aimed to evaluate the effects of pre- exercise low level laser therapy on aerobic capacity in burned patients.

low level laser therapy has a beneficial therapeutic effect on promoting aerobic capacity, improving maximum oxygen consumption and increasing treadmill time when preceding aerobic exercise training.this study was conducted to determine the effects of pre- exercise low level laser therapy on aerobic capacity in burned patients. low level laser therapy was applied to the study group for 12 weeks before aerobic exercises, three sessions / week, while control group received 12 weeks of aerobic exercises, three times weekly. patients in both groups were received the traditional physical therapy program as a routine treatment. aerobic capacity was assessed by measuring maximum oxygen consumption and time to exhaustion at baseline and after twelve weeks of interventions for both groups.

Eligibility criteria:
inclusion criteria: * sixty adult burned patients were selected under the following criteria: * patients were both males and females. * their age ranged from (25-40) years. * patients suffered from second degree thermal burns with total body surface area(tbsa) for burns ranged from 20-40%. * patients were participated in this study one month after their hospital discharge. exclusion criteria: * cardiopulmonary diseases. * any limitation in range of motion (rom) of joints of the lower limbs which may prevent adequate participation in aerobic exercise program. * leg amputation. * quadriplegia. * psychological illness or severe behavior or cognitive disorders. * patients who participated in any rehabilitation program before the study that may affect the results of the study.
trajectory of positive psychological states in patients with acs

Conditions: Acute Coronary Syndrome

Summary: the purpose of the study is to to determine the natural history of positive psychological states, health status, and functioning, over an 8 week period following admission for an acute coronary syndrome (acs). we aim to compare the changes in these factors from baseline to 8-week follow-up with corresponding changes in the completed proof-of-concept intervention trial (nct02004158).


Eligibility criteria:
inclusion criteria: * suboptimal adherence to health behaviors. this will be defined as mean item score of \<15 (suboptimal) on three medical outcomes study-specific adherence scale (mos sas) items. * submaximal self-reported optimism. this will be defined as a total score of \<30 on the life orientation test-revised (lot-r) . * submaximal self-reported positive affect. this will be defined as a total score of \<50 on the positive and negative affect schedule (panas) . exclusion criteria: * cognitive deficits, assessed via a 6-item cognitive screen used to assess appropriate participation of medically-ill patients in research studies. * medical conditions precluding interviews or likely to lead to death within 6 months, determined in consultation with the primary treatment team and cardiology co-investigator dr. januzzi. * inability to communicate in english. * inability to participate in physical activity.
a study of autologous induced islet body with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this is a single centre、single arm、open-label study，to investigate the safety and efficacy of autologous induced islet body with type 1 diabetes


Eligibility criteria:
inclusion criteria: 1. male or female, 18 to 70 years old (including 18 and 70 years old) 2. diagnosed as type i diabetes, the diagnostic criteria refer to the 1990 who diabetes diagnostic criteria: （1）diabetes symptoms (hyperglycemia caused by polydipsia, polyphagia, weight loss, itchy skin, blurred vision and other acute metabolic disorders) + random blood glucose ≥ 11.1nmol / l; （2）fasting blood glucose ≥7.0mmol/l or 75g glucose meets 2-hour blood glucose ≥11.1mmol/l. 3、voluntary informed consent is given, agree to follow the trial treatment and visit plan. note: 2 is the venous plasma glucose level, if there is no diabetes symptoms, it is necessary to repeat the test on the next day. exclusion criteria: 1. patients with acute complications of diabetes: including diabetic ketosis, diabetic ketoacidosis, diabetes, hyperglycemia, hypertonic state, etc. 2. patients with severe bacterial and viral infections 3. patients are participating in other clinical trials and treating with other immune cellular products (dc, cik, t, nk, and car t products with cd19 or other targets) 4. patients with severe cardiovascular and cerebrovascular disease (nyha class 3-4) cannot cooperate with the study 5. patients with severe liver dysfunction(liver function ast and alt exceeded 2.5 times the normal upper limit). 6. patients with kidney disease or moderate to severe renal insufficiency (renal function egfr \<60 ml/min/1.73 m2) 7. women in pregnancy (urine/blood pregnancy test positive) or lactation; men or women with pregnancy plans in the last year; patients are not guaranteed to take effective contraceptive measures during the trial; 8. patients were diagnosed as tumor or tumor chemotherapy, radiotherapy and acute uric acid nephropathy within 5 years. 9. other circumstances that researchers do not consider suitable for research. 10. withdrawal from trial, loss of follow-up or death due to other reasons 11. incomplete data, affecting effectiveness and safety judges 12. researchers believe that the need for termination of the trial is needed.
effect of hp infection on the quality of gastric mucosa preparation

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study was to evaluate the effect of helicobacter pylori infection on the quality of gastric mucosa preparation.

the purpose of this study was to evaluate the effect of helicobacter pylori infection on the quality of gastric mucosa preparation by comparing the cleanliness of gastric mucosa between patients with helicobacter pylori infection and those without helicobacter pylori infection.

Eligibility criteria:
inclusion criteria: * adults who volunteered to participate in this study and signed an informed consent form * have been tested for helicobacter pylori and have definite test results exclusion criteria: * contraindications for gastroscopy (such as severe cardiopulmonary diseases, liver and kidney dysfunction, shock, etc.) * history of upper gastrointestinal surgery * therapeutic endoscopy and emergency surgery are required * recent history of upper gastrointestinal bleeding * corrosive substance ingestion * the pregnancy * abnormal mental state cannot cooperate with the examination * patients with contraindications to the drugs used in the study.
i-123-mibg for imaging of neuroblastoma and pheochromocytoma

Conditions: Neuroblastoma; Pheochromocytoma

Summary: i-123-mibg is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors

entry criteria--histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma. exclusion criteria--pregnancy randomization--none procedure--patients will receive a dose of i-123-mibg by intravenous injection. images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. sski will be used to block thyroid uptake of free i-123-iodide

Eligibility criteria:
inclusion criteria: * histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma exclusion criteria: * pregnancy

Keywords: neuroblastoma pheochromocytoma mibg
risk factors for human corneal graft failure : a monocentric retrospective observational cohort

Conditions: Corneal Transplant Rejection

Summary: keratoplasty is one of the most common grafts and penetrating keratoplasty is still the technique most used in the world, ahead of lamellar grafts, and is estimated to represent 70% of the total. graft rejection is still the main cause of failure of this type of surgery, to the extent that nearly a third of all patients will in some way be affected by rejection in due course. numerous risk factors for rejection have been identified, whether related to the donor, the recipient, or the surgical procedure itself. in addition, many of the studies performed have used univariate analysis only, and yet there is a strong case for multivariate analysis, given the wide range of factors that need to be examined. this study seeks to analyze the rejection rates and the survival of penetrating keratoplasty for a group of patients from montpellier hospital (france).


Eligibility criteria:
inclusion criteria: -keratoplasty performed in the ophthalmology department of the chru of montpellier between 15/06/2005 and 18/09/2018 exclusion criteria: * a non-optical graft (tectonic and analgesic graft) * lamellar graft (dalk (deep anterior lamellar keratoplasty) and dsaek (descemet stripping automated endothelial keratoplasty)) * silica gel re-dried cornea, duplicates (we included each patient only once per eye) * medical record missing from the archives.

Keywords: cornea / surgery corneal transplantation* / adverse effects corneal transplantation* / methods graft rejection / prevention & control humans
cone rescue in retinitis pigmentosa by the treatment of lycium barbarum

Conditions: Retinitis Pigmentosa

Summary: objectives: to study the immediate effect and the persistent effect of lycium barbarum (lb) treatment on retinal functions, especially the cone function, and retinal structure in patients with retinitis pigmentosa (rp) design: randomised controlled double-masked trial setting: primary care clinical trial participants: 120 rp subjects will be recruited from ophthalmology department at the university of hong kong and the retina hong kong. interventions: subjects will be randomly allocated to lb (treated with lb granules) or control (treated with placebo) groups for 1 year. after the 1st year, both groups will stop the treatment and all subjects will also have the same eye exam in 6-month period for the 2nd year. main outcome measures: the primary outcome is the total sensitivity scores of 30-2 \& 60-4 programmes of humphrey visual field analysis (hvfa). the secondary outcomes are the b-wave amplitudes of full-field electroretinogram (fferg) responses, the amplitudes of direct component and induced component of multifocal electroretinogram (mferg), and the etdrs visual acuity.

the study was a randomized controlled trial with a double-masked, placebo-controlled design. all the subjects were randomly allocated into either lb (treatment) group or placebo (control) group. all the eligible subjects had the eye examination, including va using the early treatment of diabetic retinopathy study (etdrs) chart, refractions, tonometry, external and internal ocular health assessments, and fundus photo-documentation. three additional tests were conducted to investigate the functional and structural changes in the rp patients, including ganzfeld electroretinogram, humphrey visual field analyser (zeiss, dublin, usa) and spectral-domain optical coherent tomography (sd-oct) (heidelberg engineering, usa).

Eligibility criteria:
inclusion criteria: ocular conditions: * retinitis pigmentosa; * best corrected va logmar 0.20 or better; * humphrey visual field analysis (hvfa) 30-2 total mean defect \> or = 250 decibel; * intra-ocular pressure (iop) \<21 mmhg; * van herrick ratio \< or = 0.5; * no other ocular diseases dietary conditions: * fruit and vegetable intake \<10 servings/day; * spinach or kale intake \< or = serving/day; * dietary lutein intake \< or = 5.4mg/day; * no intake of cod liver oil or omega-3 capsules; * dietary lycium barbarum intake \< or =10 fruits/week; * supplement intake \< or = 5000 iu/day of vit. a and \< or = 30 iu/day of vit. e; * alcoholic consumption \< or = 3 beverages/day exclusion criteria: * bmi \> 40; * intake of any anticoagulants (especially warfarin), * pregnant or planning to be pregnant; * smoking; * other clinically significant systemic diseases, eg. diabetes, liver disease and heart disease

Keywords: retinitis pigmentosa lycium barbarum antioxidation visual field electroretinogram
study of proteins in promoting chemotherapy resistance in samples from patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about cancer and development of drug resistance in patients. purpose: this research trial is studying proteins that may promote chemotherapy resistance in samples from patients with acute myeloid leukemia.

objectives: * investigate whether changes in prosurvival signaling occur by comparing activation of the signal transducer and activator of transcription-3 (stat3) and stat5 pathways in paired diagnostic and relapse samples. * investigate changes in leukemia cell responses to extrinsic cues from the environment change, using a bone marrow stromal-cell co-culture model of chemotherapy resistance. outline: cryopreserved samples are analyzed for stat3 and stat5 expression by flow cytometry and in vitro chemotherapy sensitivity.

Eligibility criteria:
disease characteristics: * paired diagnostic and relapsed cryopreserved samples from patients with acute myeloid leukemia patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: recurrent adult acute myeloid leukemia recurrent childhood acute myeloid leukemia adult acute myeloid leukemia with 11q23 (mll) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) adult acute myeloid leukemia with del(5q)
postoperative pain control with fentanyl patch in patients undergoing mastectomy and tram or diep flap reconstruction

Conditions: Postoperative Pain After Breast Reconstruction With Abdominal Flap

Summary: the aim of this randomized, double-blind controlled trial is to determine the efficacy of transdermal fentanyl for the management of early postoperative pain in women undergoing mastectomy followed by immediate tram or diep flap reconstruction. we will examine whether the use of the fentanyl patch as a bridge between epidural and oral analgesia will improve overall pain relief compared to placebo patch. we further propose to study whether the fentanyl patch is associated with improved ability to sleep, patient satisfaction, and functional capacity at one week, and whether it is associated with different side effects than standard therapy without the patch. following informed consent, patients will undergo mastectomy and reconstruction, and receive epidural fentanyl for initial postoperative analgesia. patients will be randomized to active (25 mcg/hr duragesic) or placebo patches on postoperative day three, and the epidural will be weaned over the next 12 hours. pain intensity scores and relief from pain will be assessed every day while in the hospital and oral and iv opioid use recorded. patients will be discharged to home with a supply of 2 patches and oral medication, and will be asked to fill out a daily pain and medication log.


Eligibility criteria:
inclusion criteria: * undergoing breast reconstruction with abdominal flap * provided written, informed consent exclusion criteria: * karnofsky performance status ≥80%

Keywords: postoperative pain breast reconstruction abdominal flap breast reconstruction
pharmacokinetics and safety of hcp1105 and co-administration of hgp0918, hgp0816 in healthy male volunteers

Conditions: Hyperlipidemias

Summary: to investigate the pharmacokinetic properties and safety after administration of hcp1105 and co-administration of hgp0918, hgp0816 in healthy male volunteers

the purpose of this study is to investigate the pharmacokinetic properties and safety after administration of hcp1105 and co-administration of hgp0918, hgp0816 in healthy male volunteers

Eligibility criteria:
inclusion criteria: * subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing * healthy male volunteers, aged 19 to 55 years. * the result of body mass index(bmi) is not less than 18.5 kg/m2 , no more than 27.0 kg/m2 exclusion criteria: * •presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system * someone has a declined liver function and liver enzyme (ast, alt or total bilirubin) level exceeds more than one and a half times normal upper range * somenone has a declined kidney function and his egfr \< 60ml/min/1.73m2
gb004 in adult subjects with active ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this is a phase 1b, randomized, double-blind-, placebo-controlled, multi-center study to evaluate the safety, tolerability, and pk of gb004 in adult subjects with active ulcerative colitis. target engagement and effect of gb004 on pharmacodynamic biomarkers will be assessed.

the safety, tolerability, pharmacokinetics, and pharmacodynamics of gb004 will be explored in a phase 1b randomized controlled trial in adults subjects with active ulcerative colitis (uc). subjects will be evaluated based on incidence of aes, laboratory parameters, gb004 serum and colonic tissue concentrations, and changes in the signs and symptoms of uc.

Eligibility criteria:
inclusion criteria: * patients aged 18-74, receiving therapy for active ulcerative colitis confirmed by mayo score assessment, and evidence of colonic inflammation. exclusion criteria: * evidence of crohn's disease, indeterminate colitis, or presence of bacterial or parasitic infection. * patients receiving biologic agents and experimental agents are excluded.

Keywords: inflammatory bowel disease ulcerative colitis
an internet-based self-management program for adolescents with arthritis

Conditions: Arthritis, Juvenile Idiopathic

Summary: the purpose of this study is to demonstrate the effectiveness of the "taking charge: managing jia online" internet intervention, when compared with an attention (static education only websites) control group in improving pain and hrql as well as other health outcomes (anxiety, depression, treatment adherence, pain coping, knowledge, and self-efficacy) in adolescents with jia. the proposed study will enroll and randomize 294 adolescents with jia attending 10 pediatric rheumatology hospital clinics in the canada to either the experimental or control groups.

in summary, no rigorous internet self-management intervention has been undertaken to improve hrql, symptoms, treatment adherence, knowledge, and self-efficacy in youth with jia. the proposed "managing jia online" trial will rigorously examine the effects of this internet intervention on hrql and other health outcomes thereby filling a significant gap in our knowledge related to promotion of self-management care for adolescents with jia.

Eligibility criteria:
inclusion criteria: * age ≥12 and ≤ 18 years. * diagnosed with jia (using international league of associations for rheumatology classification criteria)83 by their rheumatologist. * adolescents and parent/ primary caregiver are able to speak and read either english or french. * participants are willing and able to complete online measures. there will be no restrictions on medication use for this study. exclusion criteria: * cognitive impairments (as assessed by reviewing medical chart and consultation with the patient's rheumatologist) * major co-morbid illnesses which may mitigate hrql assessment * excluded medical illnesses: inflammatory bowel disease, fibromyalgia, cancer, genetic disorders, diabetes * excluded psychiatric conditions: post-traumatic stress disorder, panic disorder, bipolar disorder, psychosis, depression and major mood disorders. adolescents currently on medications for major depression, bipolar disorder or psychosis would also be excluded. * adolescents that are currently participating in other cbt interventions.

Keywords: adoloescent internet self-management managing jia